跳至主要内容
临床试验/JPRN-jRCT2080223790
JPRN-jRCT2080223790已完成3 期

A phase III, double-blind, insulin-combination therapy study of imeglimin (TIMES 3)

POXEL S.A./ CMIC Co., Ltd.0 个研究点目标入组 215 人开始时间: 2018年1月30日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
215

研究概览

简要总结

Imeglimin significantly improved HbA1c in Japanese patients with insufficiently controlled type 2 diabetes by insulin and had a similar safety profile to placebo. The efficacy of imeglimin on top of insulin was sustained for 52 weeks. Imeglimin represents a potential new treatment option for this population as add-on to insulin therapy.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Main inclusion criteria:
  • 1) Insulin treated patients with type 2 diabetes mellitus, diagnosed for at least 12 weeks
  • 2) HbA1c >=7.5% and < 11.0%
  • 5) Body Mass Index (BMI) >= 18.5

排除标准

  • Main exclusion criteria:
  • 1) Patients with type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
  • 2) History of diabetic ketoacidosis or hyperosmolar non-ketotic coma
  • 3) Cardiovascular or cerebrovascular disease within 24 weeks (myocardial infarction, stroke, unstable angina etc.)
  • 4) Uncontrolled high blood pressure
  • 5) Severe impairment of hepatic function

研究者

发起方
POXEL S.A./ CMIC Co., Ltd.

相似试验